JMT108 injection for unresectable locally advanced or metastatic melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, multicenter Phase I/II study enrolls adults with unresectable locally advanced or metastatic melanoma to characterize safety, tolerability, pharmacokinetics, and preliminary efficacy of JMT108. Phase I uses a dose-escalation design to identify a recommended dose, followed by Phase IIa dose expansion and Phase IIb cohort expansion to further evaluate activity. Key eligibility includes histologic confirmation, at least one measurable lesion by RECIST 1.1, ECOG performance status 0-1, and adequate organ function. Primary endpoints focus on safety and pharmacokinetics in early stages and on objective tumor responses in the expansion cohorts.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age≥18 years old.
2. Histologically or cytologically confirmed unresectable locally advanced or metastatic melanoma and urinary tract tumors.
3. Participants with unresectable locally advanced or metastatic melanoma or urinary tract tumors who have failed prior standard treatment or have no available standard treatment will be enrolled in Phase I; those who have received or not received prior standard treatment will be enrolled in Phase IIa and Phase IIb.
4. According to the response evaluation criteria for solid tumors (RECIST 1.1), having at least one measurable lesion.
5. ECOG PS of 0-1.
6. Expected survival ≥ 3 months.
7. Participants with adequate organ functions.
8. Female and male patients of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 6 months after the last dose. Female participants of childbearing age must have a negative blood pregnancy test within 7 days before the first dose or randomization.
9. Voluntarily agree to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Within 4 weeks prior to the first administration of the investigational drug, the patient had received chemotherapy, radiotherapy, biologic therapy, endocrine therapy, targeted therapy (excluding small-molecule targeted drugs), immunotherapy, or other unmarketed investigational drugs or treatments; for small-molecule targeted drugs, use was within 2 weeks prior to the first administration of the investigational drug or within 5 half-lives of the drug (whichever is longer, not exceeding 4 weeks); and antitumor-indicated traditional Chinese medicine/products were used within 2 weeks prior to the first administration of the investigational drug.
2. Prior use of IL-2/IL-15 cytokine therapy.
3. Received major organ surgery (excluding needle biopsy) or experienced severe trauma within 4 weeks prior to the first administration of the study drug, or requires elective surgery during the study period.
4. Received systemic glucocorticoids or other immunosuppressive therapy within 14 days prior to the first use of the study drug. Exceptions include the following situations: receiving physiological replacement doses of hydrocortisone or other equivalent doses of hormonal therapy (i.e., prednisone ≤ 10 mg/day or other equivalent doses of hormones); receiving topical, ophthalmic, intra-articular, intranasal, and inhaled glucocorticoid therapy; receiving short-course glucocorticoids for preventive treatment (e.g., prevention of contrast agent allergy).
5. Known active central nervous system (CNS) metastases and/or leptomeningeal metastases. Patients with stable brain metastases who do not require local treatment for brain metastases are eligible for inclusion.
6. Patients with active infections requiring intravenous anti-infective therapy within 14 days prior to the first administration.
7. Has a history of severe cardiovascular and cerebrovascular diseases.
8. Has active or recurrent autoimmune diseases.
9. Has a known history of receiving immunotherapy with the occurrence of grade ≥3 immune-related adverse events (irAEs) (excluding immune-related endocrine abnormalities that have been stabilized) or grade ≥2 immune-related myocarditis.
10. Has a history of arterial or venous thrombosis within 6 months prior to the first administration.
11. Has a history of serous effusions such as ascites or pleural effusion requiring drainage within 14 days prior to the first administration.
12. Has a history of other malignant tumors within 5 years prior to the first administration or concurrent other malignant tumors.

Where it's running

• BeiJing Cancer Hospital EC
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Clinical Trials Information Group officer
• Email: ctr-contact@cspc.cn
• Phone: 86-0311-69085587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using tebentafusp before surgery to shrink large, unresectable uveal melanoma

  This trial will try giving tebentafusp before surgery to see if it can shrink large, unresectable primary uveal melanoma in patients who are HLA-A*02:01 positive.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania and 1 other locations · NCT06414590

• MB11 versus Opdivo for previously untreated advanced (unresectable or metastatic) melanoma

  This trial will test whether MB11, a proposed nivolumab biosimilar, works like EU- or US-sourced Opdivo for adults with untreated advanced (unresectable or metastatic) melanoma.

  Recruiting at 86 sites Phase 3 mAbxience Research S.L. · Banja Luka and 85 other locations · NCT07221734

• Combining CBL0137 with Ipilimumab and Nivolumab for Melanoma Treatment

  This study is testing a new drug called CBL0137 combined with standard melanoma treatments Ipilimumab and Nivolumab to see if it’s safe and helps people with advanced melanoma.

  Recruiting Early Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05498792

• Test a combination of SSGJ-705 and SSGJ-612 (with or without chemotherapy) in advanced HER2-expressing solid cancers

  This phase 2 study tests whether SSGJ-705 plus SSGJ-612, with or without chemotherapy, can help adults with advanced HER2-expressing solid tumors like colorectal, urothelial, breast, gastric, or biliary cancers.

  Recruiting Phase 2 Shenyang Sunshine Pharmaceutical Co., LTD. · Hangzhou, Zhejiang · NCT07646626

• Targeted cancer therapy using NEOK002 for select solid tumors

  This first-in-human study tests NEOK002, a bispecific antibody-drug conjugate, in people with locally advanced or metastatic solid tumors to see if it is safe and tolerable.

  Recruiting at 10 sites Phase 1 NEOK Bio, Inc. · Orlando, Florida and 9 other locations · NCT07612189

• NEOK001: a new B7-H3 and ROR1-targeting cancer treatment given by IV infusion

  This early-phase study tests NEOK001, a bispecific antibody-drug conjugate, in people with locally advanced or metastatic solid tumors to see if it is safe and how it behaves in the body.

  Recruiting at 9 sites Phase 1 NEOK Bio, Inc. · New York, New York and 8 other locations · NCT07612176

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.